Benuvia Operations, LLC and Chromocell Therapeutics Corp. Announce Strategic Partnership to Advance Healthcare Solutions
27 2월 2024 - 10:00PM
Benuvia Operations, LLC (“Benuvia”), a leader in pharmaceutical
innovation, and Chromocell Therapeutics Corp. (“Chromocell”), (NYSE
American: CHRO), a pioneer in the development of non-opioid pain
treatment therapeutics, are pleased to announce Chromocell’s first
Development and License Agreement (“Agreement”). Under the
Agreement, Chromocell licensed sublingual formulation of a
Diclofenac spray for the treatment of acute pain, a Rizatriptan
intranasal spray formulation and an Ondansetron sublingual spray
formulation, diversifying our pipeline of non-opioid pain treatment
therapies, while adding therapeutic options for related conditions.
This collaboration leverages the unique strengths of both
organizations to enhance patient outcomes and address unmet medical
needs.
Under the terms of the agreement, Chromocell
expects to develop clinical programs of one or more of the licensed
products within 18 months. During 2024, Chromocell intends to
complete the development and business plans for each of the three
compounds with the expectation that development would commence
following the completion of the review by the FDA. Benuvia will
support these efforts by providing manufacturing and supply
services, thereby establishing a synergistic partnership that is
expected to accelerate the path to market for innovative
therapeutic options.
This strategic alliance underscores both Benuvia
and Chromocell’s commitment to advancing healthcare through
innovative research, development, and commercialization efforts. It
also reflects the shared vision of improving patient care and
enhancing quality of life through scientific excellence and
innovation.
"We are excited to partner with Chromocell, a
company that shares our passion for innovation and our commitment
to improving patient outcomes," said Darwin Richardson, CEO of
Benuvia Operations LLC. "This partnership will leverage our
combined expertise to accelerate the development of potentially
groundbreaking therapies, aimed at marking a new era in healthcare
solutions."
Frank Knuettel II, CEO of Chromocell
Therapeutics Corp., added, "Joining forces with Benuvia represents
our first new step forward in our mission to build our portfolio
and develop novel therapeutic solutions addressing pain treatment
and related conditions with non-addictive drugs. Together, we
believe we are poised to make a profound impact on the lives of
patients around the world."
About Benuvia Operations,
LLC
Benuvia Operations, LLC is a leading
pharmaceutical company dedicated to the discovery, development, and
commercialization of innovative therapies. With a focus on
addressing unmet medical needs, Benuvia is committed to improving
patient outcomes through scientific excellence and strategic
partnerships.
About Chromocell Therapeutics
Corp.
Chromocell Therapeutics Corporation is a
clinical-stage biotechnology company focused on developing and
commercializing novel, non-opioid, non-addictive, therapeutics to
alleviate pain and other associated medical conditions. The
Company’s initial clinical focus is to selectively target the
sodium ion-channel known as NaV1.7 for the treatment of various
types of chronic neuropathic pain and eye pain. The Company’s
portfolio also includes pre-clinical work on other sodium channel
receptor subtypes and the Company intends to explore these and
other compounds for the treatment of additional pain indications.
For company updates and to learn more about Chromocell,
visit www.chromocell.com or follow us on social
media.
Forward-Looking Statements
This press release contains forward-looking
statements regarding the Company’s current expectations. These
forward-looking statements include, without limitation, references
to the Company’s expectations regarding the closing of the public
offering and its anticipated use of net proceeds from the offering.
These statements are not guarantees of future performance and are
subject to certain risks, uncertainties and assumptions that are
difficult to predict. Factors that could cause actual results to
differ include, but are not limited to, risks and uncertainties
related to the satisfaction of customary closing conditions related
to the public offering, or factors that result in changes to the
Company’s anticipated use of proceeds. These and other risks and
uncertainties are described more fully in the section captioned
“Risk Factors” in the Company’s Registration Statement on Form S-1
related to the public offering (SEC File No. 333-269188).
Forward-looking statements contained in this announcement are made
as of this date, and the Company undertakes no duty to update such
information except as required under applicable law.
For further information:
Benuvia Operations, LLCBrandon Kidd, Chief
Business Development Officerbkidd@benuvia.com
Chromocell Media and Investor
Inquires:LR Advisors LLC.Jason
Assad678-570-6791Jason@Chromocell.com
Chromocell Therapeutics (AMEX:CHRO)
과거 데이터 주식 차트
부터 9월(9) 2024 으로 10월(10) 2024
Chromocell Therapeutics (AMEX:CHRO)
과거 데이터 주식 차트
부터 10월(10) 2023 으로 10월(10) 2024